scispace - formally typeset
S

Samuel Gaugain

Researcher at University of Paris

Publications -  12
Citations -  61

Samuel Gaugain is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications receiving 18 citations. Previous affiliations of Samuel Gaugain include Paris Diderot University.

Papers
More filters
Journal ArticleDOI

Efficacy of Almitrine in the Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.

Romain Barthélémy, +10 more
- 06 Jun 2020 - 
Journal ArticleDOI

Extubation in neurocritical care patients: the ENIO international prospective study

Raphaël Cinotti, +130 more
- 29 Aug 2022 - 
TL;DR: In neurocritical care patients, extubation failure is high and is associated with unfavourable outcomes, so it will be mandatory to validate the findings in another prospective independent cohort.
Journal ArticleDOI

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Daniela Matuozzo, +1273 more
- 05 Apr 2023 - 
TL;DR: In this paper , a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 un vaccinated SARS-CoV-2-infected individuals without pneumonia was performed.
Journal ArticleDOI

CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission

Marc Pineton de Chambrun, +27 more
- 01 Sep 2019 - 
TL;DR: In this study, CAPS criteria were not associated with mortality of thrombotic APS patients requiring ICU admission, and further studies are need to evaluate the adequacy ofCAPS criteria for critically-ill APs patients.
Journal ArticleDOI

In-Hospital Mortality-Associated Factors in Patients With Thrombotic Antiphospholipid Syndrome Requiring ICU Admission.

Marc Pineton de Chambrun, +27 more
- 01 May 2020 - 
TL;DR: In-ICU anticoagulation was the only APS-specific treatment independently associated with survival for all patients, and double therapy was independentlyassociated with better survival of patients with definite/probable catastrophic APS.